197 related articles for article (PubMed ID: 27957358)
1. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma.
Akce M; Chang E; Haeri M; Perez M; Finch CJ; Udden MM; Mims MP
Case Rep Hematol; 2016; 2016():3598547. PubMed ID: 27957358
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
3. [Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH].
Fujishima T; Kawabata Y; Michishita Y; Kitabayashi A; Takahashi N
Rinsho Ketsueki; 2022; 63(10):1386-1391. PubMed ID: 36351644
[TBL] [Abstract][Full Text] [Related]
4. An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen.
Nelson B; Hong A; Iqbal F; Venkatesan R
Cureus; 2020 Jun; 12(6):e8641. PubMed ID: 32685310
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
Nwanwene K; Khan NAJ; Alsharedi M
J Investig Med High Impact Case Rep; 2021; 9():23247096211017423. PubMed ID: 34032157
[TBL] [Abstract][Full Text] [Related]
7. Plasmablastic lymphoma of the oral cavity with breast recurrence: a case report.
Samoon Z; Idrees R; Masood N; Ansari TZ
BMC Res Notes; 2015 May; 8():180. PubMed ID: 25933603
[TBL] [Abstract][Full Text] [Related]
8. A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report.
Hirosawa M; Morimoto H; Shibuya R; Shimajiri S; Tsukada J
Biomark Res; 2015; 3():28. PubMed ID: 26543559
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Reid EG; Looney D; Maldarelli F; Noy A; Henry D; Aboulafia D; Ramos JC; Sparano J; Ambinder RF; Lee J; Cesarman E; Yahyaei S; Mitsuyasu R; Wachsman W;
Blood Adv; 2018 Dec; 2(24):3618-3626. PubMed ID: 30573564
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
11. Plasmablastic lymphoma in HIV patients: Experience at a tertiary care hospital in eastern India.
Bishnu S; Banerjee S; Bandyopadhyay D; Samui S; Bhattacharya S; Bose D
Indian J Cancer; 2015; 52(4):563-7. PubMed ID: 26960478
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.
Sabry W; Wu Y; Kodad SG
Curr Oncol; 2022 Jul; 29(7):5042-5053. PubMed ID: 35877259
[TBL] [Abstract][Full Text] [Related]
13. Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation.
Hu M; Trevino J; Yang L; Cao D; Liu X; Lai J
In Vivo; 2018; 32(2):413-417. PubMed ID: 29475930
[TBL] [Abstract][Full Text] [Related]
14. Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
Foster WR; Bischin A; Dorer R; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):311-21. PubMed ID: 27234438
[TBL] [Abstract][Full Text] [Related]
15. Case of lymphadenopathy with lytic bone lesions.
Kalantri SA; Nath UK; Banerjee D; Bhattacharyya M
BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28320703
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease.
Guerrero-Garcia TA; Mogollon RJ; Castillo JJ
Leuk Res; 2017 Nov; 62():12-16. PubMed ID: 28963907
[TBL] [Abstract][Full Text] [Related]
17. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
[TBL] [Abstract][Full Text] [Related]
18. CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management.
Bindra BS; Ramineni G; Sattar Y; Khillan R
Cureus; 2019 Jul; 11(7):e5217. PubMed ID: 31565620
[TBL] [Abstract][Full Text] [Related]
19. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
20. Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.
Yamada T; Hara T; Goto N; Iwata H; Tsurumi H
Int J Hematol; 2019 Jun; 109(6):723-730. PubMed ID: 30859398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
